Moderna's mRNA Flu Shot Gains Momentum After New Trial Data

By FieldPulse Staff · May 24, 2026

Tags: launch, strategy

Moderna's mRNA flu vaccine shows promise in new trials, potentially challenging traditional vaccine leaders by late 2026.

Moderna's experimental mRNA flu vaccine is back in the spotlight after new clinical trial data suggests it may offer superior protection compared to traditional egg-based vaccines.

The once-rebuffed candidate has shown a robust immune response across multiple strains, potentially paving the way for an FDA filing in late 2026.

The news comes as a relief to Moderna, which has been looking to diversify its portfolio beyond COVID-19.

If approved, the mRNA flu shot could disrupt a market currently dominated by giants like Sanofi and GSK.

The speed of mRNA manufacturing could also allow for better matching with circulating strains, a perennial challenge for traditional vaccine makers.

"This is a significant step forward for the mRNA platform," said a biotech analyst.

"The ability to rapidly update the vaccine for new variants is a game-changer, but the real test will be long-term durability and public acceptance in a post-pandemic world.".